rosiglitazone has been researched along with isoxazoles in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 4 (66.67) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kadowaki, T | 1 |
| Hisatome, I; Ogino, K; Shigemasa, C; Shimoyama, M; Uchida, K | 1 |
| Abe, I; Eto, K; Fujishima, M; Nakamura, Y; Ohya, Y | 1 |
| Adams, AD; Berger, JP; Doebber, TW; Hu, Z; Jones, AB; MacNaul, KL; Moller, DE; Santini, C; Yuen, W | 1 |
| Chae, YN; Choi, SH; Kim, HS; Kim, JG; Kim, JK; Kim, MK; Kim, SH; Lee, CH; Lim, JI; Moon, HS; Park, SK; Shin, CY; Shin, YA; Son, MH | 1 |
| Baldelli, F; Cipriani, S; D'Amore, C; Fiorucci, S; Francisci, D; Mencarelli, A; Renga, B; Schiaroli, E | 1 |
1 review(s) available for rosiglitazone and isoxazoles
| Article | Year |
|---|---|
[Insulin-sensitizing agents].
Topics: Animals; Diabetes Mellitus; Diabetes Mellitus, Experimental; Humans; Hypoglycemic Agents; Isoxazoles; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones | 1999 |
5 other study(ies) available for rosiglitazone and isoxazoles
| Article | Year |
|---|---|
Acute hemodynamic effects of insulin-sensitizing agents in isolated perfused rat hearts.
Topics: Animals; Chromans; Dose-Response Relationship, Drug; Hemodynamics; Hypoglycemic Agents; Indomethacin; Isoxazoles; Male; NG-Nitroarginine Methyl Ester; Nitric Oxide; Perfusion; Pioglitazone; Prostaglandins; Rats; Rats, Wistar; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone; Vitamin E | 2000 |
Comparative actions of insulin sensitizers on ion channels in vascular smooth muscle.
Topics: Analysis of Variance; Animals; Barium; Calcium; Chromans; Dose-Response Relationship, Drug; Electric Stimulation; Female; Guinea Pigs; Humans; Insulin Resistance; Ion Channels; Isoxazoles; Membrane Potentials; Muscle, Smooth, Vascular; Pioglitazone; Potassium Channels; Prostaglandin D2; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2001 |
Amphipathic 3-phenyl-7-propylbenzisoxazoles; human pPaR gamma, delta and alpha agonists.
Topics: Administration, Oral; Animals; Biological Availability; COS Cells; Diabetes Mellitus, Type 2; Disease Models, Animal; Humans; Isoxazoles; Mice; Mice, Mutant Strains; Nuclear Proteins; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 2003 |
PAR-1622 is a selective peroxisome proliferator-activated receptor gamma partial activator with preserved antidiabetic efficacy and broader safety profile for fluid retention.
Topics: Adipogenesis; Administration, Oral; Animals; Blood Glucose; Blood Volume; Cells, Cultured; Diabetes Mellitus, Type 2; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Partial Agonism; Genes, Reporter; Humans; Hypoglycemic Agents; Isoxazoles; Male; Mesenchymal Stem Cells; Mice; Mice, Inbred ICR; PPAR gamma; Propionates; Rosiglitazone; Thiazolidinediones; Thiophenes; Transfection; Water-Electrolyte Balance | 2009 |
The HIV matrix protein p17 subverts nuclear receptors expression and induces a STAT1-dependent proinflammatory phenotype in monocytes.
Topics: Atherosclerosis; Cell Line; Cell Separation; gag Gene Products, Human Immunodeficiency Virus; Gene Expression Regulation; GTP-Binding Proteins; HIV Antigens; HIV Infections; HIV-1; Humans; Inflammation; Isoxazoles; Janus Kinases; Lipid Metabolism; Lipopolysaccharide Receptors; Macrophages; Monocytes; Neoplasm Proteins; Neutralization Tests; Phenotype; Phosphorylation; PPAR gamma; Receptors for Activated C Kinase; Receptors, Cell Surface; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Signal Transduction; STAT1 Transcription Factor; Thiazolidinediones; Vaccination; Vidarabine | 2012 |